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ABSTRACT 1 
Objectives. The role of endocrine therapy (ET) in high grade serous ovarian carcinoma 2 
(HGSOC) is poorly defined due to the lack of phase III data and significant heterogeneity of 3 
clinical trials performed. In this study, we sought to identify predictive factors of endocrine 4 
sensitivity in HGSOC. 5 
Methods. HGSOC patients who received at least four weeks of ET for relapsed disease 6 
following one line of chemotherapy at the Edinburgh Cancer Centre were 7 
identified. Exclusion criteria were use of endocrine therapy as maintenance therapy or of 8 
unknown duration. Duration of therapy and best CA125 response as per modified GCIG 9 
criteria were recorded. Oestrogen receptor (ER) histoscore, treatment free interval, prior lines 10 
of chemotherapy, and type of ET were evaluated as predictive factors.   11 
Results. Of 431 patients identified, 269 were eligible (77.0 % letrozole, 18.6% tamoxifen, 12 
2.2% megesterol acetate, 2.2% other). The median duration of therapy was 126 days (range 13 
28-1427 days). 32.7% remained on ET for ≥180 days and 14.1% for ≥365 days. The CA125 14 
response and clinical benefit rates (response or stable disease) were 8.1% and 40.1% 15 
respectively. ER histoscore >200 (P=0.0016) and a treatment free interval of ≥180 days 16 
(P<0.0001) were independent predictive factors upon multivariable analysis.  17 
Conclusions. ET should be considered as a viable strategy to defer subsequent chemotherapy 18 
for relapsed HGSOC. Patients with an ER histoscore >200 and a treatment free interval of 19 
≥180 days are most likely to derive benefit. 20 
 21 
 22 
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1. INTRODUCTION 23 
The majority of patients with advanced stage high grade serous ovarian carcinoma (HGSOC) 24 
will unfortunately relapse despite optimal cytoreductive surgery and platinum based 25 
chemotherapy. Symptomatic relapses are treated with further systemic chemotherapy which 26 
can be effective for some patients. However, with time, the intervals between each treatment 27 
get progressively shorter with reduced efficacy and cumulative toxicity.  28 
Endocrine therapy (ET) in relapsed HGSOC is easy to administer, has a low toxicity profile 29 
and is low cost. There is good pre-clinical evidence to support the role of oestrogen in 30 
regulating the growth of oestrogen receptor (ER) positive EOC [1, 2]. To date, more than 50 31 
phase II trials of ET in EOC have been performed with response rates between 10-15% and 32 
disease stabilisation rates of 30-40% as described in systematic reviews and meta-analyses [3, 33 
4]. Only one phase III randomised trial of tamoxifen against standard chemotherapy in the 34 
platinum resistant setting has been performed which did not demonstrate differences in 35 
overall survival [5]. As such, ET is not considered a standard of care and its use is 36 
inconsistent and variable worldwide.   37 
However, most of these trials were conducted in heavily pre-treated populations of mixed ER 38 
positive and ER negative patients [3].  In studies which pre-selected for ER status, different 39 
thresholds of ER positivity and methods of measurements were used [3]. In addition, these 40 
trials did not account for EOC comprising at least five histological subtypes which are 41 
biologically and clinically distinct [6]. 42 
The Ovarian Cancer Tissue Consortium Study found HGSOC, endometrioid and low grade 43 
serous ovarian carcinomas (LGSOC) to express the highest levels of ER (≥50% tumour 44 
nuclear staining) of 60%, 60% and 71% respectively [7]. These histologies likely represent 45 
the most endocrine sensitive subtypes with emerging retrospective data to support this. 46 
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Gershenson et al demonstrated the role of ET both as treatment for relapsed disease [8] and as 47 
first line maintenance in LGSOC [9]. Patients with LGSOC who received first line 48 
maintenance ET had a superior progression free survival of 64.9 months compared to 26.4 49 
months in those who underwent observation (p<0.001). Another retrospective study by 50 
Heinzelmann-Schwarz et al showed improvement in recurrence free survival in patients with 51 
HGSOC who received first line maintenance letrozole versus observation (p=0.035)[10]. 52 
Together, these studies illustrate the importance of performing histological subtype-specific 53 
clinical trials to derive an accurate assessment of endocrine sensitivity.  54 
Two sequential phase II studies (Bowman et al [11] and Smyth et al [12]) identified an 55 
endocrine sensitive group of ovarian cancer patients with mixed histology as those with an 56 
ER histoscore ≥150. This weighted scoring method accounts for percentage(%)  tumour cells 57 
stained and stain intensity (0 no staining, 1+ weak staining, 2+ moderate staining, 3+ strong 58 
staining). It derives a score between 0 to 300 using the formula: [1 x (% cells 1+) + 2 x (% 59 
cells 2+) + 3 x (% cells 3+)] [13]. On the basis of these data, ET has been routinely used in 60 
our centre in patients with relapsed EOC with an ER histoscore of ≥150. We sought to 61 
characterise the endocrine sensitivity of relapsed HGSOC as well as identify predictive 62 
factors in a large retrospective study.  63 
2. METHODS 64 
2.1 Patient Identification 65 
We identified patients with a historical diagnosis of grade 2 or 3 serous carcinomas [14] who 66 
received at least one line of ET from the Edinburgh Ovarian Cancer Database between 67 
January 1974 and December 2015. This database contains detailed histopathological and 68 
clinical details of patients entered prospectively as part of routine care. Communication with 69 
the Lothian Research Ethics Committee determined that retrospective analysis of outcome 70 
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using the contents of the database were deemed audit by their definition and formal ethical 71 
approval was therefore not required. 72 
2.2 Inclusion and Exclusion Criteria 73 
Patients were included if they received at least four weeks of ET as treatment for relapsed 74 
disease as determined by the treating physician, following at least one line of previous 75 
chemotherapy, and with known duration of therapy. Those who received less than four weeks 76 
of ET were deemed to have had inadequate exposure to determine sensitivity. Patients who 77 
received ET as maintenance therapy were excluded. 78 
2.3 Recorded data 79 
All baseline and treatment demographics had been prospectively collected through the 80 
Edinburgh Ovarian Cancer Database as part of routine care. All available patient electronic 81 
and paper health records were also reviewed. Treatment characteristics were recorded for the 82 
first ET received. These included: duration of therapy, lines of ET, type of ET, prior lines of 83 
chemotherapy, and ER histoscore as recorded by the pathologist at diagnosis.  The treatment 84 
free interval (TFI) was calculated from the last dose of chemotherapy to the date of ET 85 
initiation. The setting in which the last chemotherapy was received was recorded as ‘platinum 86 
sensitive’ or ‘platinum resistant ’. Patients who stopped ET due to toxicity or who were still 87 
on therapy at data cut-off were censored. 88 
     2.4 Treatment efficacy 89 
 Most clinicians used CA125 as a marker of response and did not perform radiological 90 
assessments of patients on ET until there was evidence of a significant rise in the CA125 or 91 
the patient developed symptoms. Therefore, in this non-trial setting, radiological PFS by 92 
RECIST could not be accurately defined. ET was continued until there was evidence of 93 
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symptomatic disease progression warranting further chemotherapy, or until death from 94 
ovarian cancer.  In view of this, duration of therapy was recorded as an objective end-point 95 
for this study and surrogate measure of endocrine sensitivity. The best CA125 response 96 
across the duration of therapy was also recorded. Due to the variable frequency of CA125 97 
measurements, a modified GCIG criteria was adopted [15]. Patients were evaluable for 98 
CA125 response if they had an evaluable CA125 (>70U/ml) within four weeks of starting 99 
therapy, and at least three CA125 measures if they received ET for more than 12 weeks. At 100 
least two CA125 measures were required if ET was received for 12 weeks or less with the 101 
second CA125 within 4 weeks of cessation of ET. Patients were not evaluable for CA125 102 
response if they only had one CA125 measure, and if they received ET for 12 weeks or less 103 
with no CA125 progression. The 12 week threshold was adopted as the median time to 104 
CA125 response has been shown to be 12 weeks [11]. Patients treated for less than 12 weeks 105 
with clear CA125 progression were considered evaluable. 106 
Definitions for CA125 complete response (CR), partial response (PR) and stable disease (SD) 107 
were as per GCIG criteria [15]. SD had to be maintained for at least 12 weeks from the start 108 
of therapy. Progressive disease (PD) was defined as doubling of CA125 from the baseline 109 
value. The CA125 overall response rate (ORR=CR+PR) and clinical benefit rate 1 110 
(CBR1=CR+PR+SD) were calculated and recorded. 111 
A study by Hall et al showed that the change in rate of rise in CA125 can indicate activity of 112 
cytostatic agents such as tamoxifen [16].  In view of this, the characteristics of patients who 113 
had CA125 progression by GCIG criteria, followed by <50% rise of their CA125 for at least 114 
12 weeks were also explored (delayed SD).  115 
 116 
 117 
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2.5 Statistical analysis  118 
Duration of therapy according to ER histoscore, TFI, prior lines of chemotherapy, best 119 
CA125 response and type of ET was evaluated using the Kaplan-Meier method and Cox 120 
regression models for univariable and multivariable analyses. Comparisons of CA125 ORR 121 
and CBR1 between groups were assessed using Chi-squared and Fisher’s exact tests as 122 
appropriate. Statistical analyses were performed using R version 3.3.3. 123 
3. RESULTS 124 
431 patients received at least one line of ET. 162 patients were excluded (figure 1). 269 125 
received ET as treatment for relapsed disease. 143(53.2%) were confirmed as HGSOC 126 
through contemporary pathology review conducted through other research studies, and 127 
118(43.9%) and 8(3.0%) had a historical diagnosis of grade 3 and grade 2 serous carcinomas, 128 
respectively. The median age of diagnosis was 65 years (range 28-91 years). 129 
3.1 First endocrine therapy for relapse 130 
Of 269 patients, 209 (77.7%), 55 (20.4%) and five (1.9%) patients received one, two and 131 
three lines of ET, respectively. 207 (77.0%), 50 (18.6%) and six (2.2%) patients received 132 
letrozole, tamoxifen and megesterol acetate, respectively. 156 (58.0%) patients received ET 133 
after
 
one prior line of chemotherapy, 87 (32.3%) after two lines, and 26 (9.7%) after three or 134 
more lines. 229 (85.1%) and 36 (13.4%) patients last received chemotherapy in the platinum 135 
sensitive and platinum resistant setting, respectively. ER histoscores were available in 225 136 
(83.6%) patients. The range of ER scores are illustrated in table 1. The majority of these 137 
histoscores (192, 85.3%) were from the primary chemotherapy naïve tumour.  138 
3.2 Overall CA125 response rate and duration of therapy 139 
 Of 269 patients, 257 (95.5%) stopped ET due to disease progression, 11 (4.1%) were still on ET at 140 
the time of analysis, and one (0.4%) stopped ET due to toxicity. 172 (63.9%) patients were evaluable 141 
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for CA125 response. The median number of CA125s was three (range 2-8) and six (range 3-44) in 142 
those who received 12 weeks or less of ET, and more than 12 weeks of ET, respectively. The CA125 143 
response rate was 8.1% (GCIG CR 2.9%, PR 5.2%) and the CBR was 40.1%. The pattern of CA125 144 
responses for CR and PR are shown in supplemental figure S1A and S1B, respectively. The overall 145 
median duration of therapy was 126 days (range 28-1427 days).  146 
3.3 Delayed SD patients 147 
16 patients demonstrated delayed stabilisation of their CA125 (supplemental figure S1C). 148 
The median time to first CA125 progression was 42 days (21-114 days). The delayed SD 149 
group (patients whose CA125 rose then stabilised according to the criteria outlined above) 150 
had a significantly longer median duration of therapy than those whose disease progressed on 151 
CA125 criteria without subsequent stabilisation (196 days versus 84 days, P<0.0001). The 152 
median duration of therapy between the GCIG-defined SD group and delayed SD group were 153 
comparable (P=0.288) (figure 2C). In view of this, a second CBR (CBR2) which included the 154 
delayed SD patients as part of the GCIG-defined SD cohort was calculated and compared for 155 
each variable as an exploratory analysis. 156 
3.4 ER Histoscore 157 
 148 patients with known ER histoscores had evaluable CA125 responses. There was an 158 
increasing trend in CA125 response rate of 5.8%, 8.6%, 9.1% and 14.7% in ER0-150, 159 
ER151-200, ER201-250 and ER251-300 groups, respectively. Similarly, there was an 160 
increasing trend of CBR1 with ER. These differences were not significant (table 3, figure 161 
2B). When the delayed SD patients were accounted for as part of the GCIG defined SD 162 
cohort, the CBR in the ER251-300 group was significantly higher than the ER0-150 group 163 
(CBR2 64.7% versus 37.1%; P=0.04) (table 3, figure 2D).  164 
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 The median duration of therapy was significantly longer at 140 days and 161 days in the 165 
ER201-250 (multivariable: HR 0.62, 95% CI 0.42-0.91, P=0.016) and ER251-300 groups 166 
(multivariable: HR 0.63, 95% CI 0.41-0.96, P=0.032) when compared to 88.5 days in those 167 
with ER ≤150 (table 2, figure 2A). There were no significant differences in median duration 168 
of therapy between the ER151-200 and ER ≤150 groups. 169 
3.5 Treatment free interval 170 
Of 269 patients, 259 (96.2%) received chemotherapy as their last treatment. 8(3.0%) patients 171 
received maintenance therapy and 2(0.7%) patients received secondary debulking as their last 172 
treatment and were thus excluded from this analysis. Of 259 patients, 164 (63.3%) were 173 
evaluable for CA125 responses. Patients who had a TFI 180-365 days and TFI>365 days had 174 
a significantly higher CA125 CBR1 of 50.0% (P =0.01) and 60.6% (P=0.002) when 175 
compared to 21.0 % in those with TFI<90 days (table 3, figure 2F). There were no significant 176 
differences between TFI <90days and 90-179 days.  177 
The median duration of therapy was significantly longer at 161 days and 209 days in those 178 
with TFI 180-365 days (multivariable: HR 0.32, 95% CI 0.21-0.48, P <0.0001) and TFI>365 179 
days (multivariable: HR 0.28, 95% CI 0.17-0.45, P <0.0001) compared to 84 days in those 180 
with TFI<90days (table 2, figure 2E). There were no significant differences in duration of 181 
therapy between those with TFI<90days and 90-179 days. 182 
3.6 Prior lines of chemotherapy 183 
 There was no significant difference in CA125 ORR, CBR1 or CBR2 between patients 184 
treated with different numbers of prior chemotherapy lines (table 3). The median duration of 185 
therapy was significantly longer at 142 days and 111 days in those who received ET after one 186 
(univariable: HR 0.46, 95% CI 0.30-0.70, p<0.001) and  two (univariable: HR 0.61, 95% CI 187 
0.39-0.95, p=0.03) lines of chemotherapy compared to 88.5 days after 3 lines or more (table 188 
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2, supplemental figure S2). However, these differences were not significant upon 189 
multivariable analyses (P = 0.67 and P = 0.406, respectively).  190 
3.7 Type of ET  191 
There was no significant difference in CA125 ORR, CBR1 or CBR2 between those treated 192 
with letrozole and tamoxifen (table 3). Compared to tamoxifen, patients who received 193 
letrozole had a significantly longer median duration of therapy (126 versus 98 days, 194 
univariable: HR=0.64, 95% CI 0.47-0.88, P=0.006), but the difference was not significant 195 
upon multivariable analysis (P=0.255) (table 2, supplemental figure S3). The number of 196 
patients who received megesterol acetate was too small for meaningful analysis.  197 
3.8 Characteristics of patients deriving greatest benefit from ET 198 
88 (32.7%) patients remained on ET for ≥180 days, and 38 (14.1%) for ≥365 days. Of the 38 199 
patients, 29 (76.3%) received ET after one line of chemotherapy and median TFI was 286 200 
days (range 42 – 4256 days). 34 patients had known ER histoscores, all of which were >200 201 
(25, 73.5% 201-250, 9, 26.5% >250). 33 (86.8%) patients were treated with letrozole. 28 202 
patients were evaluable for CA125 response, of which 9 (32.1%) achieved CA125 response 203 
(4 GCIG CR, 5 PR) and 16 (57.1%) achieved SD. The remaining 3 patients demonstrated 204 
delayed SD. 205 
The median duration of therapy in the 14 patients who achieved CR or PR was significantly 206 
longer at 878 days (range 180-3981 days) compared to 241 days in the 49 patients who 207 
achieved GCIG defined SD (HR = 0.30 [0.15-0.60] P < 0.001) (figure 2C).  208 
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4. DISCUSSION 209 
The main strengths of this study is in its large size with known ER status in more than 80% of 210 
the cohort. This provided sufficient power to perform comprehensive multivariable analysis 211 
in order to identify independent predictors of endocrine sensitivity. Patient and treatment 212 
demographics were also all recorded prospectively on the Edinburgh Ovarian Cancer 213 
Database thus minimising information bias.  214 
The main weaknesses were the lack of radiology response data and the use of surrogates in 215 
the form of CA125 responses and duration of therapy, thus limiting the interpretation of some 216 
of our results. As this study was not conducted within a trial setting, the CA125 time points 217 
were also heterogeneous which may have underestimated the response or stabilisation rates to 218 
ET.  Whilst all physicians started ET as treatment for relapse, the timing of treatment 219 
initiation and cessation is likely to have been inconsistent. Most ER histoscores were also 220 
recorded at the time of diagnosis by different pathologists which may have introduced 221 
interobserver variation.  222 
Although this study took place approximately over 25 years, more than half the samples were 223 
confirmed as HGSOC following contemporary pathology review. The remaining patients 224 
were almost ubiquitously diagnosed as grade 3 serous EOC which has shown to be largely 225 
concordant with HGSOC[14], with less than 3% of the analysis cohort comprising grade 2 226 
serous EOC. This provides confidence that this cohort was largely homogenous. To our 227 
knowledge, this is the biggest study performed that has attempted to quantify the efficacy of 228 
ET in relapsed HGSOC.  229 
Most prospective and retrospective studies performed to date have been performed in mixed 230 
histological subtypes [11, 17, 18]. There is clear evidence that each EOC subtype is a discrete 231 
disease with unique molecular profiles, treatment responses and patient outcomes [19]. 232 
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Recent retrospective studies have suggested a particular role for ET in the management of 233 
low grade serous ovarian cancer [8, 9]. As such, responses to ET in low grade serous ovarian 234 
cancer may have contributed to signals of efficacy in previous studies of mixed histological 235 
types and the exact sensitivity in HGSOC was unclear. 236 
Our study illustrates that the degree of ER expression is proportional to endocrine sensitivity 237 
in HGSOC. Duration of therapy increases significantly in those with ER251-300 compared to 238 
those with ER0-150 with an increasing trend in the proportion of patients demonstrating a 239 
response or stabilisation of their CA125 with increasing ER histoscores. Our study also 240 
identified a third of patients who remained on ET for more than 6 months, and nearly 15% for 241 
more than a year. Interestingly, we found that that those who sustained a complete or partial 242 
CA125 response remained on endocrine therapy for much longer than those who achieved 243 
CA125 stabilisation. Although these results are expected, it argues against indolent tumour 244 
biology as being solely responsible for these apparent long responders to ET.  245 
We also describe a small group of patients who had PD according to GCIG criteria, but who 246 
subsequently demonstrated slowing in the rate of rise in CA125. This delayed SD group 247 
behaved very similarly to the GCIG defined SD group, likely representing a cytostatic effect 248 
of ET in line with the study by Hall et al [16]. Whilst acknowledging the exploratory nature 249 
of this observation, it may suggest that CA125 stabilisation from ET can be delayed and that 250 
stopping therapy as soon as it doubles may deprive some patients of potential benefit. It also 251 
generates the hypothesis that using response as a measure of ET efficacy is less representative 252 
than that of disease stabilisation.  253 
When we accounted for the delayed SD group as part of the GCIG defined SD group, the 254 
CA125 CBR in the ER 251-300 group was significantly higher than those with ER 0-150. In 255 
this study, the differences in both duration of therapy and CA125 CBR only become apparent 256 
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in those with ER>200, although a gradient of response is likely to exist with increasing levels 257 
of ER.   258 
These findings are largely concordant with the results of previous studies conducted in 259 
patients who were unselected according to histology. Bowman et al was an open label phase 260 
II study of letrozole in 60 patients with relapsed EOC who were unselected for ER [11]. 72% 261 
had serous histology (grade unspecified). The overall CA125 ORR was 8% and CBR was 262 
32%. ER and PR expression levels were retrospectively analysed and patients with ER 263 
histoscore ≥150 and PR histoscore ≥70 were found to have a 64% disease stabilisation rate 264 
compared to 3% in those with ER histoscore <150 [11]. This prompted the study by Smyth et 265 
al which only included patients with an ER histoscore ≥150 [12]. 52% of patients in this 266 
study had serous histology. The CA125 ORR doubled to 17% with a corresponding increase 267 
in CBR of 43%. When restricted to patients with an ER 250-300, the CA125 response rate 268 
once again doubled to 33%. Notably, the radiological objective response rate increased from 269 
0% to 16% and disease stabilisation rate from 16% to 42% in this trial by Smyth et al as 270 
compared to that in Bowman et al.   271 
A more recent phase II umbrella study evaluated anastrazole in ER positive and/or PR 272 
positive (>10% nuclear staining) platinum resistant or refractory ovarian cancer [18]. The 273 
majority of patients in this study had HGSOC though the exact proportion was unspecified. It 274 
found that patients with an ER histoscore of 200-300 had a longer median progression free 275 
survival compared to those with histoscores <200. Although the difference was not 276 
statistically significant due to the small numbers of patients analysed, these findings are in 277 
line with those presented here from our centre. 278 
The data presented here are particularly pertinent as not all studies have concurred with the 279 
association between degree of ER expression and endocrine responsiveness in ovarian cancer 280 
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[17, 18, 20, 21]. It has also highlighted the use of the ER histoscore (range 0-300), a weighted 281 
score which accounts for percentage tumour cells stained and stain intensity, as an important 282 
method of determining ER positivity. The majority of aromatase inhibitor trials used a 283 
minimum threshold of more than 1% nuclear staining in order to confirm ER positivity. It is 284 
possible that the greater granularity provided by the histoscore at high levels of ER is 285 
required to discriminate patients who are most likely to benefit from ET.  286 
A few studies have attempted to establish the relationship between platinum sensitivity and 287 
endocrine sensitivity however no significant correlation has been demonstrated [4, 8, 17]. A 288 
meta-analysis of over fifty trials of ET found a lower CBR in those with platinum resistant 289 
disease compared to platinum sensitive disease although the result of was not significant[4].  290 
In our study, the platinum sensitivity of tumours at the time of ET initiation was unable to be 291 
determined. However, we found that endocrine sensitivity increased with longer treatment 292 
free intervals prior to ET initiation. The differences in duration of ET and CA125 CBR only 293 
became apparent in those with a TFI≥ 180 days when compared to TFI<90 days, a time frame 294 
which mirror the definitions used when describing platinum sensitivity. Furthermore, the 295 
majority of patients received chemotherapy for platinum sensitive disease before embarking 296 
on ET for their subsequent relapse.  297 
Although line of therapy was not an independent predictor in our study, the close association 298 
described between line of therapy and TFI in the literature[22] may suggest that patients with 299 
HGSOC are most likely to benefit from early introduction of ET for relapsed disease (i.e. 300 
when patients are more likely to have the longest TFI). This is supported by several studies of 301 
ET in patients with mixed histology [4, 23, 24]. Notably, an analysis of several tamoxifen 302 
trials compared those which had more than 50% of patients receiving only one prior line of 303 
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treatment to those with heavily pre-treated patients. The ORR in the less-treated group was 304 
25.8% compared to 4.1% in the heavily-treated group [24]. 305 
There is minimal data to demonstrate superiority of aromatase inhibitors over anti-oestrogens 306 
in ovarian cancer [17]. Although our study found no differences between letrozole and 307 
tamoxifen upon multivariable analysis, the majority of long term responders (≥365 days) in 308 
our study received letrozole contributing to the growing pool of evidence supporting letrozole 309 
as a good choice of ET in this disease. This is in keeping with the superiority of letrozole 310 
over tamoxifen demonstrated in post-menopausal women with ER positive breast cancer, in 311 
both the adjuvant and metastatic settings [25, 26] 312 
5. CONCLUSION  313 
Our data provide evidence that ET has a role to play in the management of ER positive 314 
relapsed HGSOC and quantifies the extent of benefit in this type of ovarian cancer. It 315 
supports the use of ET as a means of delaying subsequent chemotherapy. Patients with an ER 316 
histoscore >200 and a treatment free interval of 180 days or more are likely to derive the 317 
greatest benefit.  318 
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TABLE AND FIGURE LEGENDS 447 
Table 1: Characteristics of patients treated with 1
st
 ET. Rx=treatment; ER=oestrogen 448 
receptor; ET=endocrine therapy; N=number; chemo=chemotherapy; NA=not applicable. 449 
Table 2: Predictive factors of duration of endocrine therapy: univariable and multivariable 450 
analysis (n=269). N=numbers; DOT=duration of therapy; CI=confidence intervals; 451 
HR=hazard ratio; ER=oestrogen receptor; TFI=treatment free interval; ref=reference value; 452 
NE=non evaluable; Megace=megesterol acetate. 453 
Table 3: Predictive factors of CA125 response (n=172). N=numbers; CR=complete response; 454 
PR=partial response; SD=stable disease; ORR=objective response rate; CBR1=clinical 455 
benefit rate 1 (CR+PR+SD); CBR2=clinical benefit rate 2 (CR+PR+SD + 2nd SD); 456 
ER=oestrogen receptor; TFI=treatment free interval; Megace=megesterol acetate. 457 
Figure 1. Characteristics of patients treated with endocrine therapy. Rx=treatment; 458 
HGSOC= high grade serous ovarian carcinoma; G=grade. 459 
Figure 2. Duration of endocrine therapy and CA125 response rate based on ER histoscore 460 
and treatment free interval (TFI). (A) Duration of therapy versus ER histoscore, (B) CA125 461 
response rate versus ER histoscore, (C) CA125 response versus duration of therapy, (D) 462 
CA125 response rate (including SD
2 
patients as part of CBR) versus ER histoscore. (E) 463 
Duration of therapy versus TFI (F) CA125 response rate versus TFI. CR=complete response; 464 
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PR=partial response; SD=stable disease; SD
2
=delayed SD patients; CBR=clinical benefit rate 465 
(CR+PR+SD), PD=progressive disease. 466 
S1. Pattern of CA125 response in patients. (A) complete response (CR), (B) partial response 467 
(PR), (C) delayed stable disease (SD).  468 
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ABSTRACT 1 
Objectives. The role of endocrine therapy (ET) in high grade serous ovarian carcinoma 2 
(HGSOC) is poorly defined due to the lack of phase III data and significant heterogeneity of 3 
clinical trials performed. In this study, we sought to identify predictive factors of endocrine 4 
sensitivity in HGSOC. 5 
Methods. HGSOC patients who received at least four weeks of ET for relapsed disease 6 
following one line of chemotherapy at the Edinburgh Cancer Centre were 7 
identified. Exclusion criteria were use of endocrine therapy as maintenance therapy or of 8 
unknown duration. Duration of therapy and best CA125 response as per modified GCIG 9 
criteria were recorded. Oestrogen receptor (ER) histoscore, treatment free interval, prior lines 10 
of chemotherapy, and type of ET were evaluated as predictive factors.   11 
Results. Of 431 patients identified, 269 were eligible (77.0 % letrozole, 18.6% tamoxifen, 12 
2.2% megesterol acetate, 2.2% other). The median duration of therapy was 126 days (range 13 
28-1427 days). 32.7% remained on ET for ≥180 days and 14.1% for ≥365 days. The CA125 14 
response and clinical benefit rates (response or stable disease) were 8.1% and 40.1% 15 
respectively. ER histoscore >200 (P=0.0016) and a treatment free interval of ≥180 days 16 
(P<0.0001) were independent predictive factors upon multivariable analysis.  17 
Conclusions. ET should be considered as a viable strategy to defer subsequent chemotherapy 18 
for relapsed HGSOC. Patients with an ER histoscore >200 and a treatment free interval of 19 
≥180 days are most likely to derive benefit. 20 
 21 
 22 
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1. INTRODUCTION 23 
The majority of patients with advanced stage high grade serous ovarian carcinoma (HGSOC) 24 
will unfortunately relapse despite optimal cytoreductive surgery and platinum based 25 
chemotherapy. Symptomatic relapses are treated with further systemic chemotherapy which 26 
can be effective for some patients. However, with time, the intervals between each treatment 27 
get progressively shorter with reduced efficacy and cumulative toxicity.  28 
Endocrine therapy (ET) in relapsed HGSOC is easy to administer, has a low toxicity profile 29 
and is low cost. There is good pre-clinical evidence to support the role of oestrogen in 30 
regulating the growth of oestrogen receptor (ER) positive EOC [1, 2]. To date, more than 50 31 
phase II trials of ET in EOC have been performed with response rates between 10-15% and 32 
disease stabilisation rates of 30-40% as described in systematic reviews and meta-analyses [3, 33 
4]. Only one phase III randomised trial of tamoxifen against standard chemotherapy in the 34 
platinum resistant setting has been performed which did not demonstrate differences in 35 
overall survival [5]. As such, ET is not considered a standard of care and its use is 36 
inconsistent and variable worldwide.   37 
However, most of these trials were conducted in heavily pre-treated populations of mixed ER 38 
positive and ER negative patients [3].  In studies which pre-selected for ER status, different 39 
thresholds of ER positivity and methods of measurements were used [3]. In addition, these 40 
trials did not account for EOC comprising at least five histological subtypes which are 41 
biologically and clinically distinct [6]. 42 
The Ovarian Cancer Tissue Consortium Study found HGSOC, endometrioid and low grade 43 
serous ovarian carcinomas (LGSOC) to express the highest levels of ER (≥50% tumour 44 
nuclear staining) of 60%, 60% and 71% respectively [7]. These histologies likely represent 45 
the most endocrine sensitive subtypes with emerging retrospective data to support this. 46 
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Gershenson et al demonstrated the role of ET both as treatment for relapsed disease [8] and as 47 
first line maintenance in LGSOC [9]. Patients with LGSOC who received first line 48 
maintenance ET had a superior progression free survival of 64.9 months compared to 26.4 49 
months in those who underwent observation (p<0.001). Another retrospective study by 50 
Heinzelmann-Schwarz et al showed improvement in recurrence free survival in patients with 51 
HGSOC who received first line maintenance letrozole versus observation (p=0.035)[10]. 52 
Together, these studies illustrate the importance of performing histological subtype-specific 53 
clinical trials to derive an accurate assessment of endocrine sensitivity.  54 
Two sequential phase II studies (Bowman et al [11] and Smyth et al [12]) identified an 55 
endocrine sensitive group of ovarian cancer patients with mixed histology as those with an 56 
ER histoscore ≥150. This weighted scoring method accounts for percentage(%)  tumour cells 57 
stained and stain intensity (0 no staining, 1+ weak staining, 2+ moderate staining, 3+ strong 58 
staining). It derives a score between 0 to 300 using the formula: [1 x (% cells 1+) + 2 x (% 59 
cells 2+) + 3 x (% cells 3+)] [13]. On the basis of these data, ET has been routinely used in 60 
our centre in patients with relapsed EOC with an ER histoscore of ≥150. We sought to 61 
characterise the endocrine sensitivity of relapsed HGSOC as well as identify predictive 62 
factors in a large retrospective study.  63 
2. METHODS 64 
2.1 Patient Identification 65 
We identified patients with a historical diagnosis of grade 2 or 3 serous carcinomas [14] who 66 
received at least one line of ET from the Edinburgh Ovarian Cancer Database between 67 
January 1974 and December 2015. This database contains detailed histopathological and 68 
clinical details of patients entered prospectively as part of routine care. Communication with 69 
the Lothian Research Ethics Committee determined that retrospective analysis of outcome 70 
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using the contents of the database were deemed audit by their definition and formal ethical 71 
approval was therefore not required. 72 
2.2 Inclusion and Exclusion Criteria 73 
Patients were included if they received at least four weeks of ET as treatment for relapsed 74 
disease as determined by the treating physician, following at least one line of previous 75 
chemotherapy, and with known duration of therapy. Those who received less than four weeks 76 
of ET were deemed to have had inadequate exposure to determine sensitivity. Patients who 77 
received ET as maintenance therapy were excluded. 78 
2.3 Recorded data 79 
All baseline and treatment demographics had been prospectively collected through the 80 
Edinburgh Ovarian Cancer Database as part of routine care. All available patient electronic 81 
and paper health records were also reviewed. Treatment characteristics were recorded for the 82 
first ET received. These included: duration of therapy, lines of ET, type of ET, prior lines of 83 
chemotherapy, and ER histoscore as recorded by the pathologist at diagnosis.  The treatment 84 
free interval (TFI) was calculated from the last dose of chemotherapy to the date of ET 85 
initiation. The setting in which the last chemotherapy was received was recorded as ‘platinum 86 
sensitive’ or ‘platinum resistant ’. Patients who stopped ET due to toxicity or who were still 87 
on therapy at data cut-off were censored. 88 
     2.4 Treatment efficacy 89 
 Most clinicians used CA125 as a marker of response and did not perform radiological 90 
assessments of patients on ET until there was evidence of a significant rise in the CA125 or 91 
the patient developed symptoms. Therefore, in this non-trial setting, radiological PFS by 92 
RECIST could not be accurately defined. ET was continued until there was evidence of 93 
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symptomatic disease progression warranting further chemotherapy, or until death from 94 
ovarian cancer.  In view of this, duration of therapy was recorded as an objective end-point 95 
for this study and surrogate measure of endocrine sensitivity. The best CA125 response 96 
across the duration of therapy was also recorded. Due to the variable frequency of CA125 97 
measurements, a modified GCIG criteria was adopted [15]. Patients were evaluable for 98 
CA125 response if they had an evaluable CA125 (>70U/ml) within four weeks of starting 99 
therapy, and at least three CA125 measures if they received ET for more than 12 weeks. At 100 
least two CA125 measures were required if ET was received for 12 weeks or less with the 101 
second CA125 within 4 weeks of cessation of ET. Patients were not evaluable for CA125 102 
response if they only had one CA125 measure, and if they received ET for 12 weeks or less 103 
with no CA125 progression. The 12 week threshold was adopted as the median time to 104 
CA125 response has been shown to be 12 weeks [11]. Patients treated for less than 12 weeks 105 
with clear CA125 progression were considered evaluable. 106 
Definitions for CA125 complete response (CR), partial response (PR) and stable disease (SD) 107 
were as per GCIG criteria [15]. SD had to be maintained for at least 12 weeks from the start 108 
of therapy. Progressive disease (PD) was defined as doubling of CA125 from the baseline 109 
value. The CA125 overall response rate (ORR=CR+PR) and clinical benefit rate 1 110 
(CBR1=CR+PR+SD) were calculated and recorded. 111 
A study by Hall et al showed that the change in rate of rise in CA125 can indicate activity of 112 
cytostatic agents such as tamoxifen [16].  In view of this, the characteristics of patients who 113 
had CA125 progression by GCIG criteria, followed by <50% rise of their CA125 for at least 114 
12 weeks were also explored (delayed SD).  115 
 116 
 117 
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2.5 Statistical analysis  118 
Duration of therapy according to ER histoscore, TFI, prior lines of chemotherapy, best 119 
CA125 response and type of ET was evaluated using the Kaplan-Meier method and Cox 120 
regression models for univariable and multivariable analyses. Comparisons of CA125 ORR 121 
and CBR1 between groups were assessed using Chi-squared and Fisher’s exact tests as 122 
appropriate. Statistical analyses were performed using R version 3.3.3. 123 
3. RESULTS 124 
431 patients received at least one line of ET. 162 patients were excluded (fFigure 1). 269 125 
received ET as treatment for relapsed disease. 143(53.2%) were confirmed as HGSOC 126 
through contemporary pathology review conducted through other research studies, and 127 
118(43.9%) and 8(3.0%) had a historical diagnosis of grade 3 and grade 2 serous carcinomas, 128 
respectively. The median age of diagnosis was 65 years (range 28-91 years). 129 
3.1 First endocrine therapy for relapse 130 
Of 269 patients, 209 (77.7%), 55 (20.4%) and five (1.9%) patients received one, two and 131 
three lines of ET, respectively. 207 (77.0%), 50 (18.6%) and six (2.2%) patients received 132 
letrozole, tamoxifen and megesterol acetate, respectively. 156 (58.0%) patients received ET 133 
after
 
one prior line of chemotherapy, 87 (32.3%) after two lines, and 26 (9.7%) after three or 134 
more lines. 229 (85.1%) and 36 (13.4%) patients last received chemotherapy in the platinum 135 
sensitive and platinum resistant setting, respectively. ER histoscores were available in 225 136 
(83.6%) patients. The range of ER scores are illustrated in table 1. The majority of these 137 
histoscores (192, 85.3%) were from the primary chemotherapy naïve tumour.  138 
3.2 Overall CA125 response rate and duration of therapy 139 
 Of 269 patients, 257 (95.5%) stopped ET due to disease progression, 11 (4.1%) were still on ET at 140 
the time of analysis, and one (0.4%) stopped ET due to toxicity. 172 (63.9%) patients were evaluable 141 
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for CA125 response. The median number of CA125s was three (range 2-8) and six (range 3-44) in 142 
those who received 12 weeks or less of ET, and more than 12 weeks of ET, respectively. The CA125 143 
response rate was 8.1% (GCIG CR 2.9%, PR 5.2%) and the CBR was 40.1%. The pattern of CA125 144 
responses for CR and PR are shown in  supplemental figure S1A and S1BFigure 2A and 2B, 145 
respectively. The overall median duration of therapy was 126 days (range 28-1427 days).  146 
3.3 Delayed SD patients 147 
16 patients demonstrated delayed stabilisation of their CA125 (supplemental figure S1Figure 148 
2C). The median time to first CA125 progression was 42 days (21-114 days). The delayed 149 
SD group (patients whose CA125 rose then stabilised according to the criteria outlined 150 
above) had a significantly longer median duration of therapy than those whose disease 151 
progressed on CA125 criteria without subsequent stabilisation (196 days versus 84 days, 152 
P<0.0001). The median duration of therapy between the GCIG-defined SD group and 153 
delayed SD group were comparable (P=0.288) (fFigure 23C). In view of this, a second CBR 154 
(CBR2) which included the delayed SD patients as part of the GCIG-defined SD cohort was 155 
calculated and compared for each variable as an exploratory analysis. 156 
3.4 ER Histoscore 157 
 148 patients with known ER histoscores had evaluable CA125 responses. There was an 158 
increasing trend in CA125 response rate of 5.8%, 8.6%, 9.1% and 14.7% in ER0-150, 159 
ER151-200, ER201-250 and ER251-300 groups, respectively. Similarly, there was an 160 
increasing trend of CBR1 with ER. These differences were not significant (table 3, figure 161 
23B). When the delayed SD patients were accounted for as part of the GCIG defined SD 162 
cohort, the CBR in the ER251-300 group was significantly higher than the ER0-150 group 163 
(CBR2 64.7% versus 37.1%; P=0.04) (table 3, figure 23D).  164 
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 The median duration of therapy was significantly longer at 140 days and 161 days in the 165 
ER201-250 (multivariable: HR 0.62, 95% CI 0.42-0.91, P=0.016) and ER251-300 groups 166 
(multivariable: HR 0.63, 95% CI 0.41-0.96, P=0.032) when compared to 88.5 days in those 167 
with ER ≤150 (table 2, figure 23A). There were no significant differences in median duration 168 
of therapy between the ER151-200 and ER ≤150 groups. 169 
3.5 Treatment free interval 170 
Of 269 patients, 259 (96.2%) received chemotherapy as their last treatment. 8(3.0%) patients 171 
received maintenance therapy and 2(0.7%) patients received secondary debulking as their last 172 
treatment and were thus excluded from this analysis. Of 259 patients, 164 (63.3%) were 173 
evaluable for CA125 responses. Patients who had a TFI 180-365 days and TFI>365 days had 174 
a significantly higher CA125 CBR1 of 50.0% (P =0.01) and 60.6% (P=0.002) when 175 
compared to 21.0 % in those with TFI<90 days (table 3, figure 23F). There were no 176 
significant differences between TFI <90days and 90-179 days.  177 
The median duration of therapy was significantly longer at 161 days and 209 days in those 178 
with TFI 180-365 days (multivariable: HR 0.32, 95% CI 0.21-0.48, P <0.0001) and TFI>365 179 
days (multivariable: HR 0.28, 95% CI 0.17-0.45, P <0.0001) compared to 84 days in those 180 
with TFI<90days (table 2, figure 23E). There were no significant differences in duration of 181 
therapy between those with TFI<90days and 90-179 days. 182 
3.6 Prior lines of chemotherapy 183 
 There was no significant difference in CA125 ORR, CBR1 or CBR2 between patients 184 
treated with different numbers of prior chemotherapy lines (table 3). The median duration of 185 
therapy was significantly longer at 142 days and 111 days in those who received ET after one 186 
(univariable: HR 0.46, 95% CI 0.30-0.70, p<0.001) and  two (univariable: HR 0.61, 95% CI 187 
0.39-0.95, p=0.03) lines of chemotherapy compared to 88.5 days after 3 lines or more (table 188 
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2, supplemental figure S21). However, these differences were not significant upon 189 
multivariable analyses (P = 0.67 and P = 0.406, respectively).  190 
3.7 Type of ET  191 
There was no significant difference in CA125 ORR, CBR1 or CBR2 between those treated 192 
with letrozole and tamoxifen (table 3). Compared to tamoxifen, patients who received 193 
letrozole had a significantly longer median duration of therapy (126 versus 98 days, 194 
univariable: HR=0.64, 95% CI 0.47-0.88, P=0.006), but the difference was not significant 195 
upon multivariable analysis (P=0.255) (table 2, supplemental figure S32). The number of 196 
patients who received megesterol acetate was too small for meaningful analysis.  197 
3.8 Characteristics of patients deriving greatest benefit from ET 198 
88 (32.7%) patients remained on ET for ≥180 days, and 38 (14.1%) for ≥365 days. Of the 38 199 
patients, 29 (76.3%) received ET after one line of chemotherapy and median TFI was 286 200 
days (range 42 – 4256 days). 34 patients had known ER histoscores, all of which were >200 201 
(25, 73.5% 201-250, 9, 26.5% >250). 33 (86.8%) patients were treated with letrozole. 28 202 
patients were evaluable for CA125 response, of which 9 (32.1%) achieved CA125 response 203 
(4 GCIG CR, 5 PR) and 16 (57.1%) achieved SD. The remaining 3 patients demonstrated 204 
delayed SD. 205 
The median duration of therapy in the 14 patients who achieved CR or PR was significantly 206 
longer at 878 days (range 180-3981 days) compared to 241 days in the 49 patients who 207 
achieved GCIG defined SD (HR = 0.30 [0.15-0.60] P < 0.001) (figure 23C).  208 
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4. DISCUSSION 209 
The main strengths of this study is in its large size with known ER status in more than 80% of 210 
the cohort. This provided sufficient power to perform comprehensive multivariable analysis 211 
in order to identify independent predictors of endocrine sensitivity. Patient and treatment 212 
demographics were also all recorded prospectively on the Edinburgh Ovarian Cancer 213 
Database thus minimising information bias.  214 
The main weaknesses were the lack of radiology response data and the use of surrogates in 215 
the form of CA125 responses and duration of therapy, thus limiting the interpretation of some 216 
of our results. As this study was not conducted within a trial setting, the CA125 time points 217 
were also heterogeneous which may have underestimated the response or stabilisation rates to 218 
ET.  Whilst all physicians started ET as treatment for relapse, the timing of treatment 219 
initiation and cessation is likely to have been inconsistent. Most ER histoscores were also 220 
recorded at the time of diagnosis by different pathologists which may have introduced 221 
interobserver variation.  222 
Although this study took place approximately over 25 years, more than half the samples were 223 
confirmed as HGSOC following contemporary pathology review. The remaining patients 224 
were almost ubiquitously diagnosed as grade 3 serous EOC which has shown to be largely 225 
concordant with HGSOC[14], with less than 3% of the analysis cohort comprising grade 2 226 
serous EOC. This provides confidence that this cohort was largely homogenous. To our 227 
knowledge, this is the biggest study performed that has attempted to quantify the efficacy of 228 
ET in relapsed HGSOC.  229 
Most prospective and retrospective studies performed to date have been performed in mixed 230 
histological subtypes [11, 17, 18]. There is clear evidence that each EOC subtype is a discrete 231 
disease with unique molecular profiles, treatment responses and patient outcomes [19]. 232 
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Recent retrospective studies have suggested a particular role for ET in the management of 233 
low grade serous ovarian cancer [8, 9]. As such, responses to ET in low grade serous ovarian 234 
cancer may have contributed to signals of efficacy in previous studies of mixed histological 235 
types and the exact sensitivity in HGSOC was unclear. 236 
Our study illustrates that the degree of ER expression is proportional to endocrine sensitivity 237 
in HGSOC. Duration of therapy increases significantly in those with ER251-300 compared to 238 
those with ER0-150 with an increasing trend in the proportion of patients demonstrating a 239 
response or stabilisation of their CA125 with increasing ER histoscores. Our study also 240 
identified a third of patients who remained on ET for more than 6 months, and nearly 15% for 241 
more than a year. Interestingly, we found that that those who sustained a complete or partial 242 
CA125 response remained on endocrine therapy for much longer than those who achieved 243 
CA125 stabilisation. Although these results are expected, it argues against indolent tumour 244 
biology as being solely responsible for these apparent long responders to ET.  245 
We also describe a small group of patients who had PD according to GCIG criteria, but who 246 
subsequently demonstrated slowing in the rate of rise in CA125. This delayed SD group 247 
behaved very similarly to the GCIG defined SD group, likely representing a cytostatic effect 248 
of ET in line with the study by Hall et al [16]. Whilst acknowledging the exploratory nature 249 
of this observation, it may suggest that CA125 stabilisation from ET can be delayed and that 250 
stopping therapy as soon as it doubles may deprive some patients of potential benefit. It also 251 
generates the hypothesis that using response as a measure of ET efficacy is less representative 252 
than that of disease stabilisation.  253 
When we accounted for the delayed SD group as part of the GCIG defined SD group, the 254 
CA125 CBR in the ER 251-300 group was significantly higher than those with ER 0-150. In 255 
this study, the differences in both duration of therapy and CA125 CBR only become apparent 256 
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in those with ER>200, although a gradient of response is likely to exist with increasing levels 257 
of ER.   258 
These findings are largely concordant with the results of previous studies conducted in 259 
patients who were unselected according to histology. Bowman et al was an open label phase 260 
II study of letrozole in 60 patients with relapsed EOC who were unselected for ER [11]. 72% 261 
had serous histology (grade unspecified). The overall CA125 ORR was 8% and CBR was 262 
32%. ER and PR expression levels were retrospectively analysed and patients with ER 263 
histoscore ≥150 and PR histoscore ≥70 were found to have a 64% disease stabilisation rate 264 
compared to 3% in those with ER histoscore <150 [11]. This prompted the study by Smyth et 265 
al which only included patients with an ER histoscore ≥150 [12]. 52% of patients in this 266 
study had serous histology. The CA125 ORR doubled to 17% with a corresponding increase 267 
in CBR of 43%. When restricted to patients with an ER 250-300, the CA125 response rate 268 
once again doubled to 33%. Notably, the radiological objective response rate increased from 269 
0% to 16% and disease stabilisation rate from 16% to 42% in this trial by Smyth et al as 270 
compared to that in Bowman et al.   271 
A more recent phase II umbrella study evaluated anastrazole in ER positive and/or PR 272 
positive (>10% nuclear staining) platinum resistant or refractory ovarian cancer [18]. The 273 
majority of patients in this study had HGSOC though the exact proportion was unspecified. It 274 
found that patients with an ER histoscore of 200-300 had a longer median progression free 275 
survival compared to those with histoscores <200. Although the difference was not 276 
statistically significant due to the small numbers of patients analysed, these findings are in 277 
line with those presented here from our centre. 278 
The data presented here are particularly pertinent as not all studies have concurred with the 279 
association between degree of ER expression and endocrine responsiveness in ovarian cancer 280 
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[17, 18, 20, 21]. It has also highlighted the use of the ER histoscore (range 0-300), a weighted 281 
score which accounts for percentage tumour cells stained and stain intensity, as an important 282 
method of determining ER positivity. The majority of aromatase inhibitor trials used a 283 
minimum threshold of more than 1% nuclear staining in order to confirm ER positivity. It is 284 
possible that the greater granularity provided by the histoscore at high levels of ER is 285 
required to discriminate patients who are most likely to benefit from ET.  286 
A few studies have attempted to establish the relationship between platinum sensitivity and 287 
endocrine sensitivity however no significant correlation has been demonstrated [4, 8, 17]. A 288 
meta-analysis of over fifty trials of ET found a lower CBR in those with platinum resistant 289 
disease compared to platinum sensitive disease although the result of was not significant[4].  290 
In our study, the platinum sensitivity of tumours at the time of ET initiation was unable to be 291 
determined. However, we found that endocrine sensitivity increased with longer treatment 292 
free intervals prior to ET initiation. The differences in duration of ET and CA125 CBR only 293 
became apparent in those with a TFI≥ 180 days when compared to TFI<90 days, a time frame 294 
which mirror the definitions used when describing platinum sensitivity. Furthermore, the 295 
majority of patients received chemotherapy for platinum sensitive disease before embarking 296 
on ET for their subsequent relapse.  297 
Although line of therapy was not an independent predictor in our study, the close association 298 
described between line of therapy and TFI in the literature[22] may suggest that patients with 299 
HGSOC are most likely to benefit from early introduction of ET for relapsed disease (i.e. 300 
when patients are more likely to have the longest TFI). This is supported by several studies of 301 
ET in patients with mixed histology [4, 23, 24]. Notably, an analysis of several tamoxifen 302 
trials compared those which had more than 50% of patients receiving only one prior line of 303 
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treatment to those with heavily pre-treated patients. The ORR in the less-treated group was 304 
25.8% compared to 4.1% in the heavily-treated group [24]. 305 
There is minimal data to demonstrate superiority of aromatase inhibitors over anti-oestrogens 306 
in ovarian cancer [17]. Although our study found no differences between letrozole and 307 
tamoxifen upon multivariable analysis, the majority of long term responders (≥365 days) in 308 
our study received letrozole contributing to the growing pool of evidence supporting letrozole 309 
as a good choice of ET in this disease. This is in keeping with the superiority of letrozole 310 
over tamoxifen demonstrated in post-menopausal women with ER positive breast cancer, in 311 
both the adjuvant and metastatic settings [25, 26] 312 
5. CONCLUSION  313 
Our data provide evidence that ET has a role to play in the management of ER positive 314 
relapsed HGSOC and quantifies the extent of benefit in this type of ovarian cancer. It 315 
supports the use of ET as a means of delaying subsequent chemotherapy. Patients with an ER 316 
histoscore >200 and a treatment free interval of 180 days or more are likely to derive the 317 
greatest benefit.  318 
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TABLE AND FIGURE LEGENDS 447 
Table 1: Characteristics of patients treated with 1
st
 ET. Rx=treatment; ER=oestrogen 448 
receptor; ET=endocrine therapy; N=number; chemo=chemotherapy; NA=not applicable. 449 
Table 2: Predictive factors of duration of endocrine therapy: univariable and multivariable 450 
analysis (n=269). N=numbers; DOT=duration of therapy; CI=confidence intervals; 451 
HR=hazard ratio; ER=oestrogen receptor; TFI=treatment free interval; ref=reference value; 452 
NE=non evaluable; Megace=megesterol acetate. 453 
Table 3: Predictive factors of CA125 response (n=172). N=numbers; CR=complete response; 454 
PR=partial response; SD=stable disease; ORR=objective response rate; CBR1=clinical 455 
benefit rate 1 (CR+PR+SD); CBR2=clinical benefit rate 2 (CR+PR+SD + 2nd SD); 456 
ER=oestrogen receptor; TFI=treatment free interval; Megace=megesterol acetate. 457 
Figure 1. Characteristics of patients treated with endocrine therapy. Rx=treatment; 458 
HGSOC= high grade serous ovarian carcinoma; G=grade. 459 
Figure 2. Pattern of CA125 response in patients. (A) complete response (CR), (B) partial 460 
response (PR), (C) delayed stable disease (SD).  461 
Figure 23. Duration of endocrine therapy and CA125 response rate based on ER histoscore 462 
and treatment free interval (TFI). (A) Duration of therapy versus ER histoscore, (B) CA125 463 
response rate versus ER histoscore, (C) CA125 response versus duration of therapy, (D) 464 
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CA125 response rate (including SD
2 
patients as part of CBR) versus ER histoscore. (E) 465 
Duration of therapy versus TFI (F) CA125 response rate versus TFI. CR=complete response; 466 
PR=partial response; SD=stable disease; SD
2
=delayed SD patients; CBR=clinical benefit rate 467 
(CR+PR+SD), PD=progressive disease. 468 
S1Figure 2. Pattern of CA125 response in patients. (A) complete response (CR), (B) partial 469 
response (PR), (C) delayed stable disease (SD).  470 
 471 
S21. Prior lines of chemotherapy versus duration of endocrine therapy. 472 
S32. Type of endocrine therapy versus duration of endocrine therapy. 473 
 474 
 475 
Formatted: Left
Treatment for relapse (N=269)
N (%)
No. of ET received
1 209(77.7)
2 55(20.4)
3 5(1.9)
ER Histoscore
0-150 50(18.6)
151-200 55(20.4)
201-250 69(25.7)
251-300 51(19.0)
Unknown 44(16.3)
Source of ER
Primary tumour 192(85.3)
Interval debulking or 
relapse disease
27(12.0)
Unknown 6(2.7)
Type of ET
Letrozole 207(77.0)
Tamoxifen 50(18.6)
Megesterol Acetate 6(2.2)
NEa 6(2.2)
Prior lines of chemo
1 156(58.0)
2 87(32.3)
3+ 26(9.7)
Platinum sensitive 229 (85.1)
Platinum resistant 36(13.4)
Other 4(1.5)
ET=endocrine therapy; N=number; 
chemo=chemotherapy; NA=not applicable.
Table 1: Characteristics of patients treated with 1st ET
Indication
        Last regime received
a-received 2 ET sequentially due to toxicity.
Legend: Rx=treatment; ER=oestrogen receptor; 
4. Table 1 revised
Click here to download 4. Table: GYN-18-1005R1_Table1_1st_ET_patient_characteristics_revised.xlsx
median DOT
N % days HR 95% CI P HR 95% CI P
ER 
≤150 50 18.6 88.5 ref ref ref ref ref ref
151-200 55 20.4 126 0.7 0.47 - 1.03 0.071 0.76 0.50-1.16 0.201
201-250 69 25.7 140 0.59 0.4 - 0.86 0.006 0.62 0.42-0.91 0.016
251-300 51 19.0 161 0.57 0.38 - 0.84 0.005 0.63 0.41-0.96 0.032
UK 44 16.4
TFI/days
<90 63 23.4 84 ref ref ref ref ref ref
90-179 66 24.5 93.5 0.87 0.61 - 1.24 0.436 0.79 0.52-1.22 0.292
180-365 82 30.5 161 0.35 0.24 - 0.50 <0.0001 0.32 0.21-0.48 <.0001
>365 48 17.9 209 0.34 0.23 - 0.51 <0.0001 0.28 0.17-0.45 <.0001
NE 10 3.7
Therapy
Letrozole 207 77.0 126 0.64 0.47 - 0.88 0.006 0.8 0.54-1.18 0.255
Megace 6 2.2 317 0.45 0.19 - 1.06 0.068 0.17 0.17-1.99 0.391
Tamoxifen 50 18.6 98 ref ref ref ref ref ref
NEa 6 2.2
Prior lines of chemotherapy
1 156 58.0 142 0.46 0.30 - 0.70 <0.001 0.89 0.52-1.53 0.670
2 87 32.3 111 0.61 0.39 - 0.95 0.030 0.79 0.46-1.37 0.406
3+ 26 9.7 88.5 ref ref ref ref ref ref
ER=oestrogen receptor; TFI=treatment free interval; ref=reference value; NE=non evaluable
Megace=megesterol acetate.
Table 2: Predictive factors of duration of endocrine therapy: univariate and multivariable analysis (n=269)
univariate multivariate
a- patients received 2 ET sequentially due toxicity.
Legend:  N=numbers;DOT=duration of therapy; CI=confidence intervals; HR=hazard ratio; 
4. Table 2
Click here to download 4. Table: Table2_predictive_factors_ETduration.xlsx
2nd
SD
N (%) N (%) N (%) N (%) N (%)
ER
≤150 35 1(2.9) 1(2.9) 10(28.6) 1(2.9) 2(5.7) ref 12(34.4) ref 13(37.1) ref
151-200 35 1(2.9) 2(5.7) 11(31.4) 2(5.7) 3(8.6) 1.00 14(40.0) 0.805 16(45.7) 0.627
201-250 44 1(2.3) 3(6.8) 17(38.6) 4(9.1) 4(9.1) 0.688 21(47.7) 0.330 35(79.5) 0.131
251-300 34 2(5.9) 3(8.8) 11(32.4) 6(17.6) 5(14.7) 0.260 16(47.1) 0.404 22(64.7) 0.040
UK 27
TFI/days
<90 38 0 1(2.6) 7(18.4) 5(13.2) 1(2.6) ref 8(21.0) ref 13(34.2) ref
90-179 46 0 2(4.3) 11(23.9) 3(6.5) 2(4.3) 1.00 13(28.2) 0.613 16(34.7) 1
180-365 52 2(3.8) 4(7.7) 20(38.5) 6(11.5) 6(11.5) 0.231 26(50.0) 0.010 32(61.5) 0.019
 >365 28 2(7.1) 2(7.1) 13(46.4) 2(7.1) 4(14.2) 0.154 27(60.6) 0.002 19(67.7) 0.014
NE 11
Therapy
Letrozole 128 4(3.1) 6(4.7) 43(33.6) 12(9.4) 10(7.8) 0.510 53(41.4) 0.495 65(50.8) 0.437
Megace 4 0 0 2(50.0) 1(25.0) 0 1.00 2(50.0) 0.602 3(75.0) 0.310
Tamoxifen 36 1(2.8) 3(8.3) 8(22.2) 3(8.3) 4(11.1) ref 12(33.3) ref 15(41.6) ref
NEf 4
Prior lines of chemotherapy
1 97 4(4.1) 5(5.2) 29(30.0) 11(11.3) 9(9.3) 0.682 38(39.2) 0.838 49(50.5) 0.516
2 57 0 3(5.3) 22(38.6) 4(7.0) 3(5.3) 0.588 25(43.9) 0.606 29(50.9) 0.537
3+ 18 1(5.6) 1(5.6) 4(22.2) 1(5.6) 2(11.1) ref 6(33.3) ref 7(39.0) ref
e-in relation to CBR2
ER=oestrogen receptor; TFI=treatment free interval;Megace=megesterol acetate.
Legend: N=numbers; CR=complete response; PR=partial response; SD=stable disease; ORR=objective response rate; 
CBR1=clinical benefit rate 1 (CR+PR+SD); CBR2=clinical benefit rate 2 (CR+PR+SD + 2nd SD); 
Pe
a- Clinical benefit rate calculated using GCIG criteria
b-Clinical benefit rate with delayed SD patients included in the SD cohort
c-in relation to ORR
d-in relation to CBR1
f-received 2 ET sequentially due to toxicity
Pc
Table 3: Predictive factors of CA125 response (n=172)
N CR PR SD ORR CBR1a Pd CBR2b
4. Table 3
Click here to download 4. Table: Table3_predictive_factors_CA125response.xlsx
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Characteristics of patients treated with endocrine therapy.  
Rx=treatment; HGSOC= high grade serous ovarian carcinoma; G=grade. 
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PR 
CR 
Time (Months) 
Time (Months) 
ER 251-300 
ER 201-250 
ER 151-200 
ER 0-150 
>365 days 
180-365 days 
90-179 days 
<90 days 
ER histoscore 
0-150 151-200 201-250 251-300 
TFI (days) 
<90 90-179 180-365 >365 
Number at risk 
251-300 51 22 10 7 5 
201-250 69 28 17 10 6 
151-200 55 16 6 5 4 
0-150 50 10 5 4 3 
Number at risk 
≥365 48 24 12 9 5 
180-364 82 37 21 14 9 
90-179 66 11 5 4 2 
<90 63 12 3 1 0 
A B 
C D 
SD 
PR 
CR 
ER histoscore 
0-150 151-200 201-250 251-300 
SD2 
SD 
PR 
CR 
CR+PR 
SD 
SD2 
PD 
Number at risk 
CR+PR 14 14 10 9 9 
SD 55 38 17 10 5 
SD2 16 12 4 3 0 
PD 87 3 0 0 0 
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Figure 2. Duration of endocrine therapy and CA125 response rate based on ER histoscore and treatment free interval (TFI) (A) Duration of therapy versus ER 
histoscore, (B) CA125 response rate versus ER histoscore, (C) CA125 response versus duration of therapy, (D) CA125 response rate (including SD2 patients as part 
of CBR) versus ER histoscore. (E) Duration of therapy versus TFI (F) CA125 response rate versus TFI. CR=complete response; PR=partial response; SD=stable 
disease; SD2=delayed SD patients; CBR=clinical benefit rate (CR+PR+SD), PD=progressive disease. 
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Click here to download 5. Figure: GYN-18-1005R1_Figure 2_revised2.pptx
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S1. Pattern of CA125 response in patients. (A) complete response (CR), (B) partial 
response (PR), (C) delayed stable disease (SD).  
6. Supplementary Material
Click here to download 6. Supplementary Material: GYN-18-1005R1_Supp_revised2.pptx
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S2. Prior lines of chemotherapy versus duration of endocrine therapy. 
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S3. Type of endocrine therapy versus duration of endocrine therapy. 
Number at risk 
Megesterol 6 5 4 3 0 
Letrozole 207 71 33 21 13 
Tamoxifen 50 8 3 3 3 
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Highlights: 
 Endocrine therapy has efficacy in relapsed high grade serous ovarian cancer. 
 It can be used to delay subsequent chemotherapy. 
 Those with ER H-score > 200 and treatment free interval > 180 days are most likely 
to benefit. 
 
*7. Highlights (for review)
